全文获取类型
收费全文 | 225篇 |
免费 | 16篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 1篇 |
妇产科学 | 4篇 |
基础医学 | 12篇 |
口腔科学 | 1篇 |
临床医学 | 6篇 |
内科学 | 79篇 |
皮肤病学 | 1篇 |
神经病学 | 35篇 |
特种医学 | 2篇 |
外科学 | 27篇 |
一般理论 | 1篇 |
预防医学 | 4篇 |
眼科学 | 1篇 |
药学 | 8篇 |
肿瘤学 | 58篇 |
出版年
2022年 | 2篇 |
2021年 | 4篇 |
2020年 | 2篇 |
2019年 | 2篇 |
2018年 | 4篇 |
2017年 | 6篇 |
2016年 | 9篇 |
2015年 | 6篇 |
2014年 | 13篇 |
2013年 | 19篇 |
2012年 | 20篇 |
2011年 | 28篇 |
2010年 | 7篇 |
2009年 | 17篇 |
2008年 | 12篇 |
2007年 | 16篇 |
2006年 | 11篇 |
2005年 | 16篇 |
2004年 | 10篇 |
2003年 | 5篇 |
2002年 | 7篇 |
2001年 | 5篇 |
2000年 | 3篇 |
1999年 | 3篇 |
1998年 | 2篇 |
1997年 | 2篇 |
1996年 | 2篇 |
1995年 | 2篇 |
1993年 | 1篇 |
1992年 | 2篇 |
1991年 | 1篇 |
1981年 | 1篇 |
1970年 | 1篇 |
排序方式: 共有241条查询结果,搜索用时 15 毫秒
1.
Ioannis Dimarakis Aristotle D Protopapas 《European journal of cardio-thoracic surgery》2004,26(4):773-775
Vocal cord palsy after adult cardiac surgery is often attributed to non-surgical mechanisms as tracheal intubation and central venous catheterisation. It may also be caused by injury of the recurrent laryngeal nerves by surgical dissection. We hereby present a review of relevant clinical reports. The cumulative incidence was 1.1% (33 in 2980). Main reported surgical mechanisms of injury were harvesting of internal thoracic artery and topical cold cardioprotection. Bilateral nerve palsy has been lethal on at least one occasion. Where vocal cord injury followed harvesting of the left internal thoracic artery, it was reported ipsilateral to the conduit. 相似文献
2.
3.
U Germing B Hildebrandt M Pfeilst?cker T N?sslinger P Valent C Fonatsch M Lübbert D Haase C Steidl O Krieger R Stauder A A N Giagounidis C Strupp A Kündgen T Mueller R Haas N Gattermann C Aul 《Leukemia》2005,19(12):2223-2231
The international prognostic scoring system (IPSS) is considered the gold standard for risk assessment in primary myelodysplastic syndromes (MDS). This score includes several prognostic factors except serum lactate dehydrogenase (LDH). We evaluated the prognostic power of LDH as an additional variable in IPSS-based risk assessment. For this purpose, a total of 892 patients with primary MDS registered by the Austrian-German cooperative MDS study group was analyzed retrospectively. Multivariate analysis confirmed the value of established parameters such as medullary blasts, karyotype and peripheral cell counts and showed that elevated LDH was associated with decreased overall survival (P<0.00005) and increased risk of AML development (P<0.00005), independent of the system used to classify MDS (FAB or WHO). Moreover, elevated LDH was found to be a significant predictor of poor survival within each IPSS risk group and within each FAB group except RAEB-T. To exploit these results for refined prognostication, each IPSS risk group was split into two separate categories (A=normal LDH vs B=elevated LDH). Using this LDH-assisted approach, it was possible to identify MDS patients with unfavorable prognosis within the low and intermediate IPSS risk groups. We propose that the IPSS+LDH score should improve clinical decision-making and facilitate proper risk stratification in clinical trials. 相似文献
4.
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. 总被引:23,自引:0,他引:23
Aristotle Bamias Efstathios Kastritis Christina Bamia Lia A Moulopoulos Ioannis Melakopoulos George Bozas Vassiliki Koutsoukou Dimitra Gika Athanasios Anagnostopoulos Christos Papadimitriou Evagelos Terpos Meletios A Dimopoulos 《Journal of clinical oncology》2005,23(34):8580-8587
PURPOSE: Osteonecrosis of the jaw (ONJ) has been associated recently with the use of pamidronate and zoledronic acid. We studied the incidence, characteristics, and risk factors for the development of ONJ among patients treated with bisphosphonates for bone metastases. PATIENTS AND METHODS: ONJ was assessed prospectively since July 2003. The first bisphosphonate treatment among patients with ONJ was administered in 1997. Two hundred fifty-two patients who received bisphosphonates since January 1997 were included in this analysis. RESULTS: Seventeen patients (6.7%) developed ONJ: 11 of 111 (9.9%) with multiple myeloma, two of 70 (2.9%) with breast cancer, three of 46 (6.5%) with prostate cancer, and one of 25 (4%) with other neoplasms (P = .289). The median number of treatment cycles and time of exposure to bisphosphonates were 35 infusions and 39.3 months for patients with ONJ compared with 15 infusions (P < .001) and 19 months (P = .001), respectively, for patients with no ONJ. The incidence of ONJ increased with time to exposure from 1.5% among patients treated for 4 to 12 months to 7.7% for treatment of 37 to 48 months. The cumulative hazard was significantly higher with zoledronic acid compared with pamidronate alone or pamidronate and zoledronic acid sequentially (P < .001). All but two patients with ONJ had a history of dental procedures within the last year or use of dentures. CONCLUSION: The use of bisphosphonates seems to be associated with the development of ONJ. Length of exposure seems to be the most important risk factor for this complication. The type of bisphosphonate may play a role and previous dental procedures may be a precipitating factor. 相似文献
5.
Guillermo Garcia-Manero Antonio Almeida Pierre Fenaux Norbert Gattermann Aristoteles Giagounidis Stuart L. Goldberg Keiya Ozawa Jerry Weaver Valeria Santini 《Clinical Lymphoma, Myeloma & Leukemia》2019,19(4):213-219.e4
BackgroundIn the phase III MDS-005 study of patients with lower-risk, non-del(5q) myelodysplastic syndromes, lenalidomide was associated with a higher rate of ≥ 8 weeks red blood cell transfusion independence (RBC-TI) compared with placebo, but also with a higher risk of hematologic adverse events (AEs).Patients and MethodsThis analysis evaluated the ratio of clinical benefit-risk in patients treated with lenalidomide or placebo, and assessed the effect of lenalidomide dose reductions on response. Clinical benefit was a composite endpoint defined as RBC-TI, transfusion reduction ≥ 4 units packed red blood cells, hemoglobin increase ≥ 1.5 g/dL, or cytogenetic response.ResultsThe rate of clinical benefit was higher with lenalidomide than with placebo (31.9% vs. 3.8%). The ratio of response (RBC-TI and clinical benefit) to risk (hematologic AEs) favored lenalidomide over placebo. Patients who underwent ≥ 1 lenalidomide dose reduction had a longer duration of treatment, received a higher cumulative dose, and were more likely to experience clinical benefit versus patients without dose reductions.ConclusionDespite the occurrence of hematologic AEs, the overall benefit-risk profile supported lenalidomide treatment. Appropriate management of hematologic AEs by dose reductions may help patients with myelodysplastic syndromes to remain on treatment and achieve clinical benefit. 相似文献
6.
7.
Bamias A Basdanis G Xanthakis I Pavlidis N Fountzilas G 《Journal of gastrointestinal cancer》2005,36(1):29-38
Background. Although the TNM system is useful in predicting survival in resected colorectal cancer, heterogeneity within the same stages
regarding prognosis exists. We are presenting a pooled analysis of prognostic factors from two randomized studies of adjuvant
treatment conducted by the Hellenic Cooperative Oncology Group.
Patients and Methods. Patients with stage II or III colon (n=279) or rectal (n=220) cancer were included in this analysis. Following surgery, patients received: 5-fluorouracil/leucovorin (5-FU/LV) (n=135), 5-FU/LV and interferon Alfa-2a (IFNA-2a) (n=138), 5-FU/LV and pelvic chemoradiotherapy (n=106), and pelvic chemoradiotherapy alone (n=108).
Results. Median follow up was 92 mo. The number of involved lymph nodes (LNs), tumor differentiation, and the presence of regional
implants were independent prognostic factors for both OS and TTP, while nerve invasion was only significant for TTP. Patients
were stratified into three prognostic groups (low-risk: no LNs and grade 1/2; high-risk: >3 LNs and grade 3/4; intermediate-risk:
remaining patients) with distinct differences in 5-yr survival (84.7% vs 57.6% vs 32.4%) and 5-yr TTP (81.2% vs 54.5% vs 28.6%).
Conclusion. The combination of clinicopathological prognostic factors can be more informative than the traditional TNM staging system.
Such stratification may be necessary in randomized trials and could be useful in deciding the most appropriate adjuvant treatment
strategies. 相似文献
8.
Alastair J. Flint Anthony J. Rothschild Ellen M. Whyte George S. Alexopoulos Benoit H. Mulsant Patricia Marino Samprit Banerjee Cristina D. Pollari Yiyuan Wu Aristotle N. Voineskos Barnett S. Meyers 《The American journal of geriatric psychiatry》2021,29(7):645-654
ObjectiveTo examine the effect of older versus younger age on change in anthropometric and metabolic measures during extended treatment of psychotic depression with sertraline plus olanzapine.MethodsTwo hundred and sixty-nine men and women aged 18–85 years with an episode of psychotic depression were treated with open-label sertraline plus olanzapine for up to 12 weeks. Participants who remained in remission following an 8-week stabilization phase were eligible to participate in a 36-week randomized controlled trial (RCT) that compared the efficacy and tolerability of sertraline plus olanzapine with sertraline plus placebo. Weight, waist circumference and plasma lipids, glucose, HbA1c, and insulin were measured at regular intervals during the acute, stabilization and randomized phases of the study. Linear mixed models were used to analyze the trajectories of anthropometric and metabolic measures.ResultsParticipants aged 60 years or older experienced less weight gain and less increase in cholesterol during the combined acute and stabilization phases of the study compared with those aged 18–59 years. At the acute-stabilization termination visit, mean weight in older participants was 6.5 lb. less than premorbid weight, whereas it was 17.9 lb. more than premorbid weight in younger participants. In the RCT, there was a significant interaction of treatment and age group for the trajectory of weight, but the post hoc tests that compared age groups within each treatment arm were not statistically significant. There were no clinically significant differences between younger and older participants in glycemic measures.ConclusionOlder patients with psychotic depression experienced less increase in weight and total cholesterol than their younger counterparts during acute and stabilization treatment with sertraline plus olanzapine. In the older group, weight gained during the acute and stabilization phases appeared to be partial restoration of weight lost during the index episode of depression, whereas weight gain in younger participants was not. 相似文献
9.
10.